Please assess the completion status of the following clinical trial:

Trial Title: Alfapump-albumin Replacement Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant females (determined by serum pregnancy test) ≥ 18 years of age. Women of childbearing age must be prepared to use at least 1 effective (≤1% failure rate) method of contraception during the course of the study~2. Cirrhosis of the liver defined by histological and/or clinical, and/or radiological criteria~3. Presenting with refractory ascites\* and requiring periodic large volume paracentesis (large volume defined as ≥ 5 L to accord with the clinical guidance of EASL, European Association for the Study of the Liver, which recommends withdrawal of 5 L should precipitate administration of albumin).~4. Capable of giving written informed consent, willing to comply with study procedures and ability to operate the device~Exclusion Criteria:~1. Gastrointestinal haemorrhage over the last 7 days~2. Renal failure defined as serum creatinine higher than or equal to 2 mg/dl~3. Severe coagulopathy defined as prothrombin time greater than 40% more than Upper Limit of Normal~4. Platelet count of less than 40,000 / μL unless platelet therapy is given at the time of surgery~5. Clinical Evidence of recurrent bacterial peritonitis, defined as 2 or more episodes over the last 6 months or a single episode within the last 2 weeks~6. Clinical evidence of recurrent urinary infections, defined as 2 or more episodes over the last 6 months or a single episode within the last 2 weeks~7. Clinical evidence of loculated ascites~8. Advanced hepatocellular carcinoma, defined as exceeding Milan criteria~9. Obstructive uropathy, residual urinary volume exceeding 100ml, or any bladder anomaly which might contraindicate implantation of the device~10. Concurrently implanted with any other Active Implantable Medical Device, including, but not limited to cardiac pacemaker or cardiovertering defibrillator~11. Pregnant females or females anticipating pregnancy during study period~12. Patients currently enrolled in another interventional clinical study~13. Other concomitant disease or condition likely to significantly decrease life expectancy or present anaesthetic risk (e.g., moderate to severe congestive heart failure)~14. Known presence of human immunodeficiency virus (HIV)~15. Immuno-modulatory treatment (including azathioprine, methotrexate, anti-TNF therapies) used within last 4 months~16. Known or suspected hepatic or extra hepatic malignancy, unless adequately treated or in complete remission for ≥ 3 years~17. BMI\>40 presenting a risk for surgery and tunnelled lines~18. Patients with contraindications for general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alfapump with albumin treatment (Type: EXPERIMENTAL): patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).